The DOI matches its Crossref record; 111 of the 114 references it cites were found in a registry or an index, and 3 are not checked yet.
The Amyloid Cascade Hypothesis in Alzheimer’s Disease: It’s Time to Change Our Mind
Open accessAbstract
Since its discovery in 1984, the beta amyloid peptide has treaded the boards of neurosciences as the star molecule in Alzheimer's disease pathogenesis. In the last decade, however, this vision has been challenged by evidence-based medicine showing the almost complete failure of clinical trials that experimented anti-amyloid therapies with great hopes. Moreover, data have accumulated which clearly indicate that this small peptide plays a key role in the physiological processes of memory formation. In the present review, we will discuss the different aspects of the amyloid cascade hypothesis, highlighting its pros and cons, and we will analyse the results of the therapeutic approaches attempted to date that should change the direction of Alzheimer's disease research in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, more integrative hypotheses have suggested that inflammation, excitatory‐inhibitory imbalance, or vascular impairment is involved in the series of initial reactions that eventually become chronic and result in irreversible brain dyshomeostasis, neurodegeneration, and AD [42, 66, 69].”
From Gliovascular alterations in sporadic and familial Alzheimer's disease: APOE3 Christchurch homozygote glioprotection (2023) · cites this paper as [69]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Under healthy conditions, soluble monomeric Aβ contributes to synaptic regulation, neuronal signaling, and neuroprotection through modulation of calcium homeostasis, metal ion binding, and antimicrobial defense [41–43].”
From Toward a Unified Framework in Molecular Neurobiology of Alzheimer’s Disease: Revisiting the Pathophysiological Hypotheses (2026) · cites this paper as [42]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
(2023) · doi:10.1126/science · Cited by 6,063
Colman (2022) · doi:10.1073/pnas · Cited by 4,370
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Bloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194
Neurotrophic and Neurotoxic Effects of Amyloid β Protein: Reversal by Tachykinin Neuropeptides
Yankner, B. A., Duffy, L. K., & Kirschner, D. A. (1990) · Science · doi:10.1126/science.2218531 · Cited by 1,975
Research works printed but not linked: 2
- [5]Ferreira S.T. Lourenco M.V. Oliveira M.M. De Felice F.G. Soluble amyloid-β oligomers as synaptotoxins leading to cognitive impairment in Alzheimer’s disease. Front. Cell. Neurosci. 2015 26 9 191 PMC4443025 26074767
- [90]Wang H. Song L. Laird F. Wong P.C. Lee H.K. BACE1 knockouts display deficits in activity-dependent potentiation of synaptic transmission at mossy fiber to CA3 synapses in the hippocampus. J. Neurosci. 2008 28 8677 8681 [http://dx.doi.org/ 10.1523/JNEUROSCI.2440-08.2008]. 18753368 PMC2728626 · DOI
Cited by
Sorted by citations
Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
Breijyeh, Z., & Karaman, R. (2020) · Molecules · doi:10.3390/molecules25245789 · Cited by 2,789
Wang, C., & Holtzman, D. M. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0478-5 · Cited by 615
Alzheimer’s disease: Recent treatment strategies
Vaz, M., & Silvestre, S. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173554 · Cited by 547
The multiplex model of the genetics of Alzheimer's disease
Sims, R., Hill, M., & Williams, J. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0599-5 · Cited by 466
GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., & Zhang, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721135 · Cited by 463
Multicomponent peptide assemblies
Raymond, D. M., & Nilsson, B. L. (2018) · Chemical Society Reviews · doi:10.1039/c8cs00115d · Cited by 348
The Physiological Roles of Amyloid-β Peptide Hint at New Ways to Treat Alzheimer's Disease
Brothers, H. M., Gosztyla, M. L., & Robinson, S. R. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00118 · Cited by 314
The amyloid cascade hypothesis: an updated critical review
Kepp, K. P., Robakis, N. K. R. K., Høilund‐Carlsen, P. F., Sensi, S. L., & Vissel, B. (2023) · Brain · doi:10.1093/brain/awad159 · Cited by 315
Alzheimer’s Disease: Key Insights from Two Decades of Clinical Trial Failures
Kim, C. K., Lee, Y. R., Ong, L., Gold, M., Kalali, A., & Sarkar, J. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215699 · Cited by 241
The duality of amyloid-β: its role in normal and Alzheimer’s disease states
Azargoonjahromi, A. (2024) · Molecular Brain · doi:10.1186/s13041-024-01118-1 · Cited by 214
Understanding the Amyloid Hypothesis in Alzheimer’s Disease
Paroni, G., Bisceglia, P., & Seripa, D. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180802 · Cited by 194
Mechanisms of Pathogenic Tau and Aβ Protein Spreading in Alzheimer’s Disease
d’Errico, P., & Meyer‐Luehmann, M. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00265 · Cited by 191
HOOK, V. Y. H., Yoon, M. C., Mosier, C., Ito, G., Podvin, S., Head, B. P., Rissman, R. A., O’Donoghue, A. J., & Hook, G. (2020) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2020.140428 · Cited by 177
Zeller, M. V., Dias, D., Sebastião, A. M., & Valente, C. A. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210268 · Cited by 179
Yu, S. P., Jiang, M. Q., Shim, S. S., Pourkhodadad, S., & Wei, L. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00636-1 · Cited by 178
Role of the peripheral innate immune system in the development of Alzheimer's disease
Page, A. Y. L., Dupuis, G., Frost, E. H., Larbi, A., Pawelec, G., Witkowski, J. M., & Fülöp, T. (2017) · Experimental Gerontology · doi:10.1016/j.exger.2017.12.019 · Cited by 162
Boyd, R. J., Avramopoulos, D., Jantzie, L. L., & McCallion, A. S. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02584-x · Cited by 168
Xu, C., Wu, J. S., Wu, Y., Ren, Z., Yao, Y., Chen, G., Fang, E. F., Noh, J. H., Liu, Y., Wei, L., et al. (2021) · Theranostics · doi:10.7150/thno.62376 · Cited by 151
Copper Toxicity Links to Pathogenesis of Alzheimer’s Disease and Therapeutics Approaches
Ijaz, H. W., Wang, W., & Lang, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207660 · Cited by 146
The emerging role of exosomes in Alzheimer’s disease
Zhang, T., Ma, S., Lv, J., Wang, X., Afewerky, H. K., Li, H. R., & Lu, Y. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101321 · Cited by 141
Drug development for alzheimer’s disease: Microglia induced neuroinflammation as a target
Dong, Y., Li, X., Cheng, J., & Hou, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030558 · Cited by 136
Scopolamine, a Toxin-Induced Experimental Model, Used for Research in Alzheimer’s Disease
Chen, W. N., & Yeong, K. Y. (2020) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527319666200214104331 · Cited by 136
Theofilas, P., Ehrenberg, A. J., Nguy, A. K., Thackrey, J. M., Dunlop, S. R., Mejia, M. B., Alho, A. T. D. L., Leite, R. E. P., Rodriguez, R. D., Suemoto, C. K., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.09.007 · Cited by 134
Zaman, M., Khan, A. N., Wahiduzzaman, Zakariya, S. M., & Khan, R. H. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.05.109 · Cited by 135
Majdi, A., Sadigh‐Eteghad, S., Aghsan, S. R., Farajdokht, F., Vatandoust, S. M., Abbas-Abad, A. N., & Mahmoudi, J. (2020) · Reviews in the Neurosciences · doi:10.1515/revneuro-2019-0089 · Cited by 130
WEIRD bodies: mismatch, medicine and missing diversity
Gurven, M., & Lieberman, D. E. (2020) · Evolution and Human Behavior · doi:10.1016/j.evolhumbehav.2020.04.001 · Cited by 130
Uddin, M. S., & Kabir, M. T. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00197 · Cited by 121
Han, H., Zhao, Y., Du, J., Wang, S., Yang, X., Li, W., Song, J., Zhang, S., Zhang, Z., Tan, Y., et al. (2023) · Immunity & Ageing · doi:10.1186/s12979-023-00390-4 · Cited by 122
ApoE and Neurodegenerative Diseases in Aging
Yin, Y., & Wang, Z. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-1117-8_5 · Cited by 111
Li, H., Liu, C.-C., Zheng, H., & Huang, T. Y. (2018) · Translational Neurodegeneration · doi:10.1186/s40035-018-0139-3 · Cited by 103
Inflammatory Cascade in Alzheimer’s Disease Pathogenesis: A Review of Experimental Findings
de Oliveira, J., Kucharska, E., Garcez, M. L., Rodrigues, M. S., Quevedo, J., Moreno‐González, I., & Budni, J. (2021) · Cells · doi:10.3390/cells10102581 · Cited by 110
Anti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis
Fedele, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914499 · Cited by 102
Self-citationOuyang, Q., Liu, K., Zhu, Q., Deng, H., Le, Y., Ouyang, W., Yan, X., Zhou, W., & Tong, J. (2022) · Small · doi:10.1002/smll.202107534 · Cited by 94
microRNA-Based Biomarkers in Alzheimer’s Disease (AD)
Zhao, Y., Jaber, V. R., Alexandrov, P. N., Vergallo, A., Lista, S., Hampel, H. J., & Lukiw, W. J. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.585432 · Cited by 99
Gouveia, F., Camins, A., Ettcheto, M., Bicker, J., Falcão, A. C., Cruz, M. T., & Fortuna, A. C. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101612 · Cited by 99
Pharmacotherapy Evolution in Alzheimer’s Disease: Current Framework and Relevant Directions
Miculas, D. C., Negru, P. A., Bungau, S. G., Behl, T., Hassan, S. S. U., & Tit, D. M. (2022) · Cells · doi:10.3390/cells12010131 · Cited by 96
Baicalein inhibits heparin-induced Tau aggregation by initializing non-toxic Tau oligomer formation
Sonawane, S. K., Uversky, V. N., & Chinnathambi, S. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-021-00704-3 · Cited by 95
The informed road map to prevention of Alzheimer Disease: a call to arms
McDade, E., Llibre-Guerra, J. J., Holtzman, D. M., Morris, J. C., & Bateman, R. J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00467-y · Cited by 89
Infectious hypothesis of Alzheimer disease
Seaks, C. E., & Wilcock, D. M. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008596 · Cited by 93
Sang, Z., Wang, K., Zhang, P., Shi, J., Liu, W., & Tan, Z. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.07.021 · Cited by 89
Is tau in the absence of amyloid on the Alzheimer’s continuum?: A study of discordant PET positivity
Weigand, A. J., Bangen, K. J., Thomas, K. R., Delano‐Wood, L., Gilbert, P. E., Brickman, A. M., Bondi, M. W., & Initiative, A. D. N. (2019) · Brain Communications · doi:10.1093/braincomms/fcz046 · Cited by 93
Antidiabetic Drugs for the Risk of Alzheimer Disease in Patients With Type 2 DM Using FAERS
Akimoto, H., Negishi, A., Oshima, S., Wakiyama, H., Okita, M., Horii, N., Inoue, N., Ohshima, S., & Kobayashi, D. (2020) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317519899546 · Cited by 89
Cell models for Alzheimer’s and Parkinson’s disease: At the interface of biology and drug discovery
Cetin, S., Knez, D., Gobec, S., Kos, J., & Pišlar, A. H. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112924 · Cited by 92
Uddin, M. S., Kabir, M. T., Tewari, D., Mathew, B., & Aleya, L. (2019) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2019.134836 · Cited by 83
Nanoparticle-Based Technology Approaches to the Management of Neurological Disorders
Sim, T. M., Dinesh, T., Dheen, S. T., Bay, B., & Srinivasan, D. K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176070 · Cited by 84
Amyloid-β Peptide Is Needed for cGMP-Induced Long-Term Potentiation and Memory
Palmeri, A., Ricciarelli, R., Gulisano, W., Rivera, D., Rebosio, C., Calcagno, E., Tropea, M. R., Conti, S., Das, U., Roy, S., et al. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.3607-16.2017 · Cited by 79
Self-citationMunawara, U., Catanzaro, M., Xu, W., Tan, C., Hirokawa, K., Bosco, N., Dumoulin, D., Khalil, A., Larbi, A., Lévesque, S., et al. (2021) · Immunity & Ageing · doi:10.1186/s12979-021-00236-x · Cited by 74
Shi, L., Westwood, S., Baird, A. L., Winchester, L. M., Dobričić, V., Kilpert, F., Hong, S., Franke, A., Hye, A., Ashton, N. J., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.06.4951 · Cited by 70
Kim, N. Y., Lee, H. Y., Choi, Y. Y., Mo, S. J., Jeon, S., Ha, J. H., Park, S. D., Shim, J.-J., Lee, J., & Chung, B. G. (2024) · Nano Convergence · doi:10.1186/s40580-024-00413-w · Cited by 81
Phytotherapy: A promising approach for the treatment of Alzheimer's disease
John, O. O., Amarachi, I. S., Chinazom, A. P., Adaeze, E., Kale, M. B., Umare, M. D., & Upaganlawar, A. B. (2022) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2021.100030 · Cited by 69
cAMP, cGMP and Amyloid β: Three Ideal Partners for Memory Formation
Ricciarelli, R., & Fedele, E. (2018) · Trends in Neurosciences · doi:10.1016/j.tins.2018.02.001 · Cited by 70
Self-citationMukhopadhyay, S., & Banerjee, D. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215065 · Cited by 66
Panitch, R., Hu, J., Chung, J., Zhu, C., Meng, G., Xia, W., Bennett, D. A., Lunetta, K. L., Ikezu, T., Au, R., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01266-z · Cited by 59
Pathogenesis of sporadic Alzheimer's disease by deficiency of NMDA receptor subunit GluN3A
Zhong, W., Wu, A., Berglund, K., Gu, X., Jiang, M. Q., Talati, J., Zhao, J., Wei, L., & Yu, S. P. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12398 · Cited by 59
Targeting Aggrephagy for the Treatment of Alzheimer’s Disease
Malampati, S., Song, J., Tong, B. C., Nalluri, A., Yang, C., Wang, Z., Sreenivasmurthy, S. G., Zhu, Z., Liu, J., Su, C.-F., et al. (2020) · Cells · doi:10.3390/cells9020311 · Cited by 60
Sang, Z., Wang, K., Shi, J., Liu, W., & Tan, Z. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.06.026 · Cited by 59
Protein aggregation: Consequences, mechanism, characterization and inhibitory strategies
Majid, N., & Khan, R. H. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.125123 · Cited by 59
Fülöp, T., Witkowski, J. M., Larbi, A., Khalil, A., Herbein, G., & Frost, E. H. (2019) · Journal of NeuroVirology · doi:10.1007/s13365-019-00732-3 · Cited by 59
Physiological Roles of Monomeric Amyloid-β and Implications for Alzheimer’s Disease Therapeutics
Jeong, H., Shin, H., Hong, S., & Kim, Y. S. (2022) · Experimental Neurobiology · doi:10.5607/en22004 · Cited by 59
Morató, X., Pytel, V., Jofresa, S., Ruiz, A., & Boada, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169305 · Cited by 53
The Anti-Amyloid Monoclonal Antibody Lecanemab: 16 Cautionary Notes
Kepp, K. P., Sensi, S. L., Johnsen, K. B., Barrio, J. R., Høilund‐Carlsen, P. F., Neve, R. L., Alavi, A. A., Herrup, K., Perry, G. L., Robakis, N. K. R. K., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230099 · Cited by 56
Targeting Alzheimer’s Disease: The Critical Crosstalk between the Liver and Brain
Huang, Z., Lin, H. W. (., Zhang, Q., & Zong, X. (2022) · Nutrients · doi:10.3390/nu14204298 · Cited by 50
Andrade, S., Nunes, D., Dabur, M., Ramalho, M. J., Pereira, M. D. C., & Loureiro, J. A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010212 · Cited by 55
Alzheimer’s disease: a mini-review for the clinician
Madnani, R. S. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1178588 · Cited by 56
Campora, M., Canale, C., Gatta, E., Tasso, B., Laurini, E., Relini, A., Pricl, S., Catto, M., & Tonelli, M. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00624 · Cited by 51
Diagnostic Accuracy of Blood-Based Biomarker Panels: A Systematic Review
Hardy-Sosa, A., León‐Arcia, K., Llibre‐Guerra, J. J., Berlanga‐Acosta, J., Baez, S. D. L. C., Guillén, G. E., & Valdes-Sosa, P. A. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.683689 · Cited by 57
Hakim, A. M. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01020 · Cited by 56
Diagnosis and Treatment of Alzheimer’s Disease:
Bomasang-Layno, E., & Bronsther, R. (2021) · Delaware Journal of Public Health · doi:10.32481/djph.2021.09.009 · Cited by 60
Mamsa, S. S. A., & Meloni, B. P. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.759729 · Cited by 50
Wang, Y., Yang, Y., Zhang, S., Li, C.-T., & Zhang, L. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.12.013 · Cited by 49
Association of CSF Aβ 38 Levels With Risk of Alzheimer Disease–Related Decline
Cullen, N., Janelidze, S., Palmqvist, S., Stomrud, E., Mattsson, N., Hansson, O., & Initiative, A. D. N. (2021) · Neurology · doi:10.1212/wnl.0000000000013228 · Cited by 47
Transcriptional Networks of Microglia in Alzheimer’s Disease and Insights into Pathogenesis
Chew, G., & Petretto, E. G. (2019) · Genes · doi:10.3390/genes10100798 · Cited by 46
Borsom, E. M., Conn, K. A., Keefe, C. R., Herman, C., Orsini, G. M., Hirsch, A. H., Avila, M. P., Testo, G., Jaramillo, S. A., Bolyen, E. K., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.03458-22 · Cited by 45
Smith, E. S., Porterfield, J. E., & Kannan, R. M. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.02.009 · Cited by 45
Cooper, L. L., O’Donnell, A., Beiser, A., Thibault, E. G., Sanchez, J. S., Benjamin, E. J., Hamburg, N. M., Vasan, R. S., Larson, M. G., Johnson, K. A., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.1261 · Cited by 45
Hein, Z. M., Karikalan, B., Gopalakrishna, P. K., Dhevi, K., Alkatiri, A., Hussan, F., Mohd Moklas, M. A., Jagadeesan, S., Che Ramli, M. D., Che Mohd Nassir, C. M. N., et al. (2026) · Molecular Neurobiology · doi:10.1007/s12035-025-05602-0 · Cited by 43
Atlante, A., Valenti, D., Latina, V., & Amadoro, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147722 · Cited by 44
Alzheimer’s disease: amyloid-based pathogenesis and potential therapies
Zhou, Y., Sun, Y., Ma, Q., & Liu, Y. (2018) · Cell Stress · doi:10.15698/cst2018.07.143 · Cited by 45
Srinivasan, E., Chandrasekhar, G., Chandrasekar, P., Anbarasu, K., Vickram, A., Tayubi, I. A., Rajasekaran, R., & Karunakaran, R. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.753146 · Cited by 41
Abbas, K., Mustafa, M., Alam, M., Habib, S., Ahmad, W., Adnan, M., Hassan, M. I., & Usmani, N. (2025) · Neurogenetics · doi:10.1007/s10048-025-00821-y · Cited by 48
Lucke Wold, B. (2017) · Journal of Neurology and Neurosurgery · doi:10.19104/jnn.2017.40 · Cited by 41
Glymour, M. M., Brickman, A. M., Mika Kivimaki, B., Mayeda, E. R., Chêne, G., Dufouil, C., & Manly, J. J. (2018) · European Journal of Epidemiology · doi:10.1007/s10654-018-0418-4 · Cited by 41
Bajda, M., Łażewska, D., Godyń, J., Zaręba, P., Kuder, K., Hagenow, S., Łątka, K., Stawarska, E., Stark, H., Kieć‐Kononowicz, K., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111785 · Cited by 40
Alzheimer’s Disease Targeted Nano-Based Drug Delivery Systems
Altinoglu, G., & Adalı, T. (2019) · Current Drug Targets · doi:10.2174/1389450120666191118123151 · Cited by 41
Exploitation of Marine Molecules to Manage Alzheimer’s Disease
Silva, M., Seijas, P., & Otero, P. (2021) · Marine Drugs · doi:10.3390/md19070373 · Cited by 45
Lorenzo, D. D. (2024) · ChemMedChem · doi:10.1002/cmdc.202400180 · Cited by 46
Shetty, A. K., Upadhya, R., Madhu, L. N., & Kodali, M. (2019) · Aging and Disease · doi:10.14336/ad.2019.0330 · Cited by 38
Late-onset unexplained epilepsy: What are we missing?
Sarkis, R. A., Willment, K., Pennell, P. B., & Marshall, G. A. (2019) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2019.106478 · Cited by 38
Jiang, J. H., Liu, H., Wang, Z., Tian, H., Wang, S., Yang, J., & Ren, J. (2021) · PLoS ONE · doi:10.1371/journal.pone.0259530 · Cited by 39
Lung endothelium, tau, and amyloids in health and disease
Balczon, R., Lin, M. T., Voth, S. B., Nelson, A. R., Schupp, J. C., Wagener, B. M., Pittet, J., & Stevens, T. (2023) · Physiological Reviews · doi:10.1152/physrev.00006.2023 · Cited by 40
Drosophila Model for Studying Gut Microbiota in Behaviors and Neurodegenerative Diseases
Chiang, M.-H., Ho, S.-M., Wu, H.-Y., Lin, Y.-C., Tsai, W.-H., Wu, T., Lai, C., & Wu, C. (2022) · Biomedicines · doi:10.3390/biomedicines10030596 · Cited by 39
Clark, J., Kayed, R., Kayed, R., Abate, G., Kinnon, P., & Kinnon, P. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.835288 · Cited by 38
Valentin‐Escalera, J., Leclerc, M., & Calon, F. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230118 · Cited by 37
Ophthalmic Biomarkers for Alzheimer’s Disease: A Review
Majeed, A., Marwick, B., Yu, H., Fadavi, H., & Tavakoli, M. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.720167 · Cited by 39
Feinkohl, I., Schipke, C. G., Kruppa, J., Menne, F., Winterer, G., Pischon, T., & Peters, O. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200046 · Cited by 38
Shin, S. J., Jeong, Y.-O., Jeon, S. G., Kim, S., Lee, S.-K., Choi, H. S., Im, C. S., Kim, S. H., Kim, S. H., Park, J. H., et al. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.10.003 · Cited by 35
Schwartz, M., Ramos, J. M. P., & Ben-Yehuda, H. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1900844 · Cited by 31
Batool, Z., Chen, J., Gao, Y., Lu, L. W., Xu, H., Liu, B., Wang, M., & Chen, F. (2022) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c06206 · Cited by 33
Smil, V. (2023) · The MIT Press eBooks · doi:10.7551/mitpress/15070.001.0001 · Cited by 32
Iman, K., Mirza, M. U., Mazhar, N., Vanmeert, M., Irshad, I., & Kamal, M. A. (2018) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527317666180115162422 · Cited by 32
Metadata
- Authors
- Ricciarelli, R., & Fedele, E.
- Affiliations
- University of Genoa (IT)
- Corresponding author
- Ricciarelli, Roberta
- Fedele, Ernesto
- Venue
- Current Neuropharmacology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2017-07-31
- Volume
- 15
- Issue
- 6
- Pages
- 926-935
- ISSN
- 1570-159X (ISSN-L)
- PMC
- PMC5652035
- OpenAlex
- W2581177196
- Cited by
- 380
- References
- 111
- Citations by year
- 2026: 22 · 2025: 30 · 2024: 49 · 2023: 60 · 2022: 53 · 2021: 58 · 2020: 51 · 2019: 33 · 2018: 13 · 2017: 11
- FWCI
- 21.86
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc
- Locations
- Current Neuropharmacology (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid hypothesis, Alzheimer's disease, amyloid-beta, anti-amyloid therapy, clinical trial failure, memory formation, Alzheimer's disease pathogenesis
- MeSH terms
- Alzheimer Disease, Animals, Brain, Humans, Amyloid beta-Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
